Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 17 | 2025 | 391 | 3.770 |
Why?
|
| Renal Replacement Therapy | 6 | 2023 | 50 | 1.920 |
Why?
|
| Nephrology | 3 | 2021 | 26 | 1.310 |
Why?
|
| Renal Dialysis | 5 | 2023 | 191 | 1.260 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2024 | 8 | 0.890 |
Why?
|
| Complement C3 | 1 | 2024 | 20 | 0.890 |
Why?
|
| Critical Care | 2 | 2018 | 218 | 0.870 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 66 | 0.810 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2025 | 325 | 0.770 |
Why?
|
| Kidney | 3 | 2025 | 722 | 0.730 |
Why?
|
| Hepatorenal Syndrome | 5 | 2023 | 11 | 0.710 |
Why?
|
| Anticoagulants | 3 | 2020 | 277 | 0.640 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 215 | 0.620 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 117 | 0.590 |
Why?
|
| Hemofiltration | 1 | 2017 | 8 | 0.550 |
Why?
|
| Postoperative Complications | 1 | 2024 | 1080 | 0.540 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 78 | 0.530 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 303 | 0.520 |
Why?
|
| Heparin | 1 | 2016 | 87 | 0.470 |
Why?
|
| Critical Illness | 1 | 2017 | 312 | 0.450 |
Why?
|
| Colloids | 1 | 2013 | 4 | 0.430 |
Why?
|
| Isotonic Solutions | 1 | 2013 | 20 | 0.420 |
Why?
|
| Albumins | 1 | 2013 | 30 | 0.420 |
Why?
|
| Fluid Therapy | 1 | 2013 | 80 | 0.410 |
Why?
|
| Mycobacterium Infections | 1 | 2011 | 10 | 0.370 |
Why?
|
| Mycobacterium | 1 | 2011 | 28 | 0.370 |
Why?
|
| Peritonitis | 1 | 2011 | 27 | 0.370 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 33 | 0.360 |
Why?
|
| Vasoconstrictor Agents | 3 | 2023 | 81 | 0.340 |
Why?
|
| Sepsis | 1 | 2013 | 233 | 0.340 |
Why?
|
| Humans | 25 | 2025 | 52469 | 0.330 |
Why?
|
| Prognosis | 7 | 2025 | 2113 | 0.320 |
Why?
|
| Angiotensinogen | 3 | 2013 | 12 | 0.300 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 3050 | 0.290 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 243 | 0.250 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2025 | 17 | 0.230 |
Why?
|
| Male | 12 | 2025 | 26794 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2024 | 250 | 0.200 |
Why?
|
| Aged | 8 | 2025 | 10193 | 0.200 |
Why?
|
| Creatinine | 3 | 2018 | 159 | 0.190 |
Why?
|
| Intensive Care Units | 2 | 2014 | 235 | 0.190 |
Why?
|
| Female | 13 | 2025 | 28192 | 0.180 |
Why?
|
| Middle Aged | 9 | 2025 | 13084 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 802 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2021 | 423 | 0.150 |
Why?
|
| Rats | 1 | 2024 | 3180 | 0.150 |
Why?
|
| Uremia | 1 | 2018 | 13 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 38 | 0.140 |
Why?
|
| Vancomycin | 1 | 2018 | 86 | 0.140 |
Why?
|
| Mice | 2 | 2025 | 5936 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 80 | 0.130 |
Why?
|
| Citrates | 1 | 2016 | 10 | 0.130 |
Why?
|
| Echocardiography | 1 | 2019 | 414 | 0.120 |
Why?
|
| Research Design | 1 | 2018 | 358 | 0.120 |
Why?
|
| Proteomics | 1 | 2018 | 327 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 944 | 0.120 |
Why?
|
| Arterial Pressure | 1 | 2015 | 44 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 599 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 399 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 5471 | 0.110 |
Why?
|
| Empyema, Pleural | 1 | 2014 | 12 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2016 | 224 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 496 | 0.110 |
Why?
|
| Renin | 1 | 2013 | 18 | 0.100 |
Why?
|
| Hypertension | 2 | 2019 | 568 | 0.100 |
Why?
|
| Resuscitation | 1 | 2013 | 71 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 220 | 0.100 |
Why?
|
| Renin-Angiotensin System | 1 | 2013 | 58 | 0.100 |
Why?
|
| Pneumonia | 1 | 2014 | 125 | 0.100 |
Why?
|
| Animals | 2 | 2025 | 13455 | 0.100 |
Why?
|
| Disease Progression | 3 | 2025 | 872 | 0.100 |
Why?
|
| Adult | 5 | 2020 | 14151 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 266 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 221 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 203 | 0.090 |
Why?
|
| Time Factors | 1 | 2017 | 2989 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 1038 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2013 | 1348 | 0.080 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 55 | 0.070 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 48 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1044 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 2449 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2017 | 459 | 0.050 |
Why?
|
| Cisplatin | 1 | 2025 | 284 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2025 | 6643 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2025 | 909 | 0.050 |
Why?
|
| Lypressin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 8 | 0.040 |
Why?
|
| Catheterization | 1 | 2021 | 96 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 1480 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 1897 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 671 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 30 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 64 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 69 | 0.040 |
Why?
|
| Colorimetry | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2019 | 265 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 95 | 0.030 |
Why?
|
| Manikins | 1 | 2018 | 35 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1216 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 719 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 139 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 135 | 0.030 |
Why?
|
| United States | 2 | 2021 | 5225 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 3945 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 293 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 124 | 0.030 |
Why?
|
| Octreotide | 1 | 2015 | 9 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 602 | 0.030 |
Why?
|
| Midodrine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 112 | 0.030 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2014 | 10 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2014 | 17 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1076 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 61 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 509 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1550 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 183 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 294 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 253 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 491 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 602 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 313 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 462 | 0.020 |
Why?
|
| Heart Failure | 1 | 2017 | 579 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 932 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2288 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 3413 | 0.010 |
Why?
|